Sarilumab is proving effective for treating RA. In a clinical trial, pregabalin did not meet its endpoint for treating post-traumatic peripheral neuropathic pain. And a 12-hour ibuprofen patch is in development…
Living with RA: Study Examines the Value of Patient Involvement in Creating Clinical Practice Guidelines
“The lived experience with RA is itself a valuable form of expertise,” writes Dr. Liana Fraenkel, MD, MPH, and her colleagues in their latest research. To examine the value of this expertise and how it can be incorporated into clinical practice guidelines, researchers developed 18 questions for which two panels—one physician dominated and one comprising entirely patients—would develop recommendations. For a majority of these questions, the patient panel made the same recommendations as the physician panel, with similar recommendation strengths…
Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.
In Europe, an etanercept biosimilar is getting closer to being approved to treat RA and more, and in the U.S., an application for an adalimumab biosimilar has been submitted for FDA approval. Also, an analysis of methotrexate use in the U.S. shows that therapy may actually be underused for RA…
ACPA-Positive & ACPA-Negative Patients with RA: The Difference Begins in the Lungs
A new study from Stockholm, Sweden, strengthens the link between the lungs and anti-citrullinated protein antibody (ACPA)–positive RA. After analyzing the bronchial tissue of untreated patients with early RA, researchers found the patients’ lungs had signs of immune cell accumulation and activation…
More Evidence Biomarkers Predict RA Relapse with DMARD Taper
NEW YORK (Reuters Health)—For rheumatoid arthritis (RA) patients in stable remission, a panel of inflammatory markers in blood can help predict the odds of relapse when disease-modifying anti-rheumatic drug (DMARD) therapy is tapered, say researchers from Germany. The multibiomarker disease activity (MBDA) score, when combined with anticitrullinated protein antibody (ACPA) testing, can predict relapse in…
Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…
Dr. Michael Weinblatt Discusses Current & Future RA Therapies
According to former ACR President Michael Weinblatt, MD, the future of drug therapies for patients with RA rests in the careful and intelligent prescription of current medications and treatment combinations, as well as better patient access through lower costs…
NPs & PAs May Improve Care in Rheumatology Practices
A recent study examined the outcomes of care for RA patients provided by nurse practitioners or physician assistants working in tandem with rheumatologists, compared with that provided exclusively by rheumatologists. Over the two-year course of the study, results indicated that not only was care not compromised, but RA disease activity control may actually have been slightly better in these practices…
Etanercept Biosimilars Promising in Clinical Studies
In multiple clinical studies, investigational biosimilars for etanercept were shown to be safe and effective for treating rheumatoid arthritis and moderate to severe plaque psoriasis…
Bronchial Tissue Immune Activation Seen in Early Rheumatoid Arthritis
NEW YORK (Reuters Health)—Patients with untreated early rheumatoid arthritis (RA) show signs of immune activation and local inflammation in their bronchial tissues, researchers from Sweden report. Previous studies have shown that patients with RA have shared citrullinated epitopes in the lungs and joints, as well as anticitrullinated protein antibodies (ACPA) in bronchoalveolar lavage (BAL), suggesting…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 30
- Next Page »